Company Overview and News

Industry Leader Yields 11%, Major Growth Starting In Q2 2018, Industry Turnaround

2018-05-17 seekingalpha
It reported record Q1 '18 earnings and closed on a major deal at the start of Q2 '18.

USAC / USA Compression Partners LP 10-Q (Quarterly Report)

usac_Current folio_10Q Table of Contents

USA Compression Partners' (USAC) CEO Eric Long on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
USA Compression Partners LP (NYSE:USAC) Q1 2018 Earnings Conference Call May 9, 2018 11:00 AM ET

USAC / USA Compression Partners LP 8-K (Current Report)

usac_Current Folio_8K_Earnings Release

Archrock Is Grabbing The Cash Flow For A Potential Payout Leap

2018-05-01 seekingalpha
Leasing rates are rising as the industry cyclically recovers and rising oil prices increase the amount of gas produced as an extra to the oil targeted.

Evercore (EVR) Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Evercore First Quarter 2019 Financial Results Conference Call. During today's presentation, all parties will be in listen-only mode. Following the presentation, the conference call will be open for questions. This conference call is being recorded today, Wednesday, April 25, 2018.

What's in Store for McDermott (MDR) This Earnings Season?

2018-04-19 zacks
McDermott International, Inc. (MDR - Free Report) is expected to release first-quarter 2018 results before the opening bell on Apr 24. In the preceding three-month period, the company delivered a positive earnings surprise of 233.33% on the back of strong project execution, and increased marine and fabrication activities. Further, the company reported an average positive surprise of 247.07% in the trailing four quarters.

USAC, CCLP: Will the Outperformance Continue?

2018-04-18 marketrealist
USA Compression Partners (USAC), CSI Compressco (CCLP), and Archrock Partners (APLP) are up 11%, 32%, and 4%, respectively, so far in 2018. The compression services MLPs outperformed the Alerian MLP ETF (AMLP) and the Energy Select Sector SPDR ETF (XLE) during this period. AMLP and XLE are down nearly 7% and 1%, respectively, year-to-date.

Top MLP Gainers in the Week Ending April 13

2018-04-17 marketrealist
Legacy Reserves (LGCY), an upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP gainer in the week ending April 13, 2018. Legacy Reserves rallied 17.4% last week. The rally was mainly due to strong gains in crude oil prices.

USAC / USA Compression Partners LP / Energy Transfer Equity, L.P. - SCHEDULE 13D (Activist Investment)


USAC / USA Compression Partners LP / Energy Transfer Equity, L.P. - SCHEDULE 13D (Activist Investment)


USAC / USA Compression Partners LP 8-K/A (Current Report)


USAC / USA Compression Partners LP 8-K (Current Report)


USAC / USA Compression Partners LP 8-K (Current Report)


CSI Compressco LP Throws The Bank Away

2018-04-06 seekingalpha
Money is there to expand working capital as activity increases from the tripled backlog for the plant and to order more equipment.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 90290N109